[public-health] MEDICAL: DISEASES: MULTIPLE SCLEROSIS : MEDICAL: RESEARCH : MEDICAL: PHARMACY PHARMACEUTICAL PHARMACOLOGY: DRUGS: New Multiple Sclerosis Drug, Backed by 40 Years of Research, Could Halt Disease

 

.

.

MEDICAL: DISEASES: MULTIPLE SCLEROSIS :

MEDICAL: RESEARCH :

MEDICAL: PHARMACY PHARMACEUTICAL PHARMACOLOGY: DRUGS:

New Multiple Sclerosis Drug,
Backed by 40 Years of Research, Could Halt Disease

.

.

New Multiple Sclerosis Drug,
Backed by 40 Years of Research, Could Halt Disease

March 29, 2017

by Nina Bai

Medical Xpress

https://medicalxpress.com/news/ 2017-03-multiple-sclerosis-drug-years-halt.html

.

A shorter URL for the above link:

.

http://tinyurl.com/mnrcbmq

.

.

A newly approved drug that is the first to reflect the current scientific understanding of multiple sclerosis (MS)  is holding new hope for the hundreds of thousands Americans living with the disease.

.

It also highlights the importance of clinician-scientists like UC San Francisco’s Stephen Hauser, MD, who are working to transform research into cures for patients.

The Food and Drug Administration on Tuesday approved ocrelizumab (brand name Ocrevus) to treat both relapsing-remitting MS and primary progressive MS, the first time a therapy has been available for severe forms of the disease.

The drug, the first that targets B cells in the human body, grew out of the work of Hauser, chair of neurology at UCSF, whose team persevered for decades in elucidating the science behind MS, defending findings that contradicted long-standing assumptions and translating the science into a therapy.

A Devastating Disease

In MS, the immune system attacks the protective myelin covering around nerve cells, stripping them like insulation from electrical wires. We now know, thanks in large part to Hauser and his colleagues, that immune cells known as B cells lead the attack, mistaking myelin protein for harmful agents. The attacks cause inflammation that disrupts the communication between nerve cells.

The first episode of MS typically strikes in early adulthood and the disease advances over the years to devastating disability. Depending on where the inflammation occurs  the brain, spinal cord or optic nerves patients can develop muscle weakness, incoordination, bladder difficulties, visual impairment and cognitive problems.
In relapsing-remitting MS, the most common form, people experience intermittent flares of symptoms followed by periods of complete or partial recovery.

About one in 10 people with MS have the more intractable primary progressive form and experience steady worsening of symptoms without remission.

There are no cures for MS, and existing treatments only partially reduce symptoms of relapsing-remitting MS. No therapies at all have been effective for primary progressive MS  until now. The approval of the ocrelizumab comes after studies that have shown remarkable results for both forms of the disease.

.

snip

.

Topics Discussed in This Article

.

The Promise of the New Drug

Hope for Patients

Finding a Better Model

A Second Eureka Moment

Importance of Clinician-Scientists

.

.

Positive multiple sclerosis clinical trial suggests ‘unprecedented’ effects in relapsing form of the disease

https://medicalxpress.com/news/ 2016-12-positive-multiple-sclerosis-clinical-trial.html

.

A shorter URL for the above link:

.

http://tinyurl.com/k5wk9l4

More information: Xavier Montalban et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis, New England Journal of Medicine (2017). DOI: 10.1056/NEJMoa1606468

https://medicalxpress.com/journals/new-england-journal-of-medicine/

Journal reference: New England Journal of Medicine
Provided by: University of California, San Francisco

http://tinyurl.com/k5wk9l4

http://dx.doi.org/10.1056/NEJMoa1606468

http://tinyurl.com/lsv48zy

.

.

Sincerely,
David Dillard
Temple University
(215) 204 – 4584
jwne@temple.edu
http://workface.com/e/daviddillard

Net-Gold
https://groups.io/g/Net-Gold
http://groups.yahoo.com/group/net-gold
http://listserv.temple.edu/archives/net-gold.html
https://groups.io/org/groupsio/Net-Gold/archives
http://net-gold.3172864.n2.nabble.com/

Temple University and Google Sites Research Guides
AND Discussion Group Directory
http://tinyurl.com/ngda2hk

OR

https://sites.google.com/site/researchguidesonsites/

FAKE NEWS
https://sites.google.com/site/fakenewsresearchguide/

RESEARCH PAPER WRITING
http://guides.temple.edu/research-papers

EMPLOYMENT
http://guides.temple.edu/employment-guide

INTERNSHIPS
http://guides.temple.edu/employment-internships

HOSPITALITY
http://guides.temple.edu/hospitality-guide

DISABILITIES AND EMPLOYMENT
http://guides.temple.edu/c.php?g=134557

INDOOR GARDENING
https://groups.io/g/indoor-gardening

Educator-Gold
http://groups.yahoo.com/group/Educator-Gold/

K12ADMINLIFE
http://groups.yahoo.com/group/K12AdminLIFE/

PUBLIC HEALTH RESOURCES INCLUDING EBOLA
http://guides.temple.edu/public-health-guide

STATISTICS SOURCES RESEARCH GUIDE
http://guides.temple.edu/statistics-sources

Social Work and Social Issues Discussion Group
https://groups.io/g/social-work

Tourism Discussion Group
https://groups.io/g/Tourism

Digital Scholarship Discussion Group
https://groups.io/g/DigitalScholarship/threads
https://listserv.temple.edu/cgi-bin/wa?A0=DIGITAL-SCHOLARSHIP
https://groups.yahoo.com/neo/groups/digital-scholarship/info
https://digitalscholarshipandscholarlypublication.wordpress.com/

Copyright Research Guide
Copyright, Intellectual Property and Plagiarism Sources
http://guides.temple.edu/copyright-plagiarism

Fair Use
http://guides.temple.edu/fair-use

Blog
https://educatorgold.wordpress.com/

Articles by David Dillard
https://sites.google.com/site/daviddillardsarticles/

Information Literacy (Russell Conwell Guide)
http://tinyurl.com/78a4shn

Twitter: davidpdillard

Temple University Site Map
https://sites.google.com/site/templeunivsitemap/home

Bushell, R. & Sheldon, P. (eds),
Wellness and Tourism: Mind, Body, Spirit,
Place, New York: Cognizant Communication Books.
Wellness Tourism: Bibliographic and Webliographic Essay
David P. Dillard
http://tinyurl.com/o4pn4o9

Rail Transportation
https://groups.io/org/groupsio/RailTransportation

INDOOR GARDENING
Improve Your Chances for Indoor Gardening Success
http://tech.groups.yahoo.com/group/IndoorGardeningUrban/

SPORT-MED
https://www.jiscmail.ac.uk/lists/sport-med.html
http://groups.yahoo.com/group/sports-med/
http://listserv.temple.edu/archives/sport-med.html

HEALTH DIET FITNESS RECREATION SPORTS TOURISM
https://groups.yahoo.com/neo/groups/healthrecsport/info
http://listserv.temple.edu/archives/health-recreation-sports-tourism.html

.

.

Please Ignore All Links to JIGLU
in search results for Net-Gold and related lists.
The Net-Gold relationship with JIGLU has
been terminated by JIGLU and these are dead links.
http://groups.yahoo.com/group/Net-Gold/message/30664
http://health.groups.yahoo.com/group/healthrecsport/message/145
Temple University Listserv Alert :
Years 2009 and 2010 Eliminated from Archives
https://sites.google.com/site/templeuniversitylistservalert/

.

.

.

.

.

-=-=-=-=-=-=-=-=-=-=-=-

.

.

.

.

Groups.io Links:

You receive all messages sent to this group.

View/Reply Online (#519):

https://groups.io/g/public-health/message/519

View All Messages In Topic (1):

https://groups.io/g/public-health/topic/4844942

.

.

Advertisements
[public-health] MEDICAL: DISEASES: MULTIPLE SCLEROSIS : MEDICAL: RESEARCH : MEDICAL: PHARMACY PHARMACEUTICAL PHARMACOLOGY: DRUGS: New Multiple Sclerosis Drug, Backed by 40 Years of Research, Could Halt Disease

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s